Home » Stocks » MIRM

Mirum Pharmaceuticals, Inc. (MIRM)

Stock Price: $18.84 USD 0.26 (1.40%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $18.80 -0.04 (-0.21%) Jan 21, 4:43 PM
Market Cap 555.16M
Revenue (ttm) n/a
Net Income (ttm) -84.02M
Shares Out 25.13M
EPS (ttm) -9.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $18.84
Previous Close $18.58
Change ($) 0.26
Change (%) 1.40%
Day's Open 18.68
Day's Range 17.96 - 19.20
Day's Volume 70,614
52-Week Range 9.38 - 26.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients with Primary Sclerosing Cholangitis

Business Wire - 1 week ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Corporate Update

Business Wire - 1 week ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 2 weeks ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

Zacks Investment Research - 4 weeks ago

Mirum Pharmaceuticals (MIRM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel...

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel...

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Virtual Investor Day 2020

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #AASLD--Mirum Data Presented at AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with ALGS Treated with Maralixibat

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents New Data From its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the AASLD Annual Meeting

Seeking Alpha - 2 months ago

MoA reduces bile acid systemic levels. Potential utility across wide range of rare liver diseases.

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020

PRNewsWire - 3 months ago

FOSTER CITY, Calif., Oct. 15, 2020 /PRNewswire/ -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies f...

Business Wire - 4 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Investor Conferences in September

Business Wire - 4 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum initiates rolling NDA submission for maralixibat for the treatment of cholestatic pruritus in patients with ALGS & launches EAP

Business Wire - 4 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients with PFIC2 at Digital International Liver Congress

Business Wire - 5 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

Business Wire - 5 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

Seeking Alpha - 8 months ago

Mirum Pharmaceuticals: Undervalued Rare Disease Player With Clear Path To Market

The Motley Fool - 1 year ago

It appears the FDA is willing to work with Mirium to get maralixibat approved as quickly as possible.

GuruFocus - 1 year ago

Mirium Pharmaceuticals Inc. (NASDAQ:MIRM) shares continue to soar, having nearly tripled since mid-December after it had a successful pre-New Drug Application meeting with the Food and Drug Ad...

The Motley Fool - 1 year ago

This newly public drug developer tripled its stock price in November following positive FDA news.

The Motley Fool - 1 year ago

The company's clinical trial is taking an important step forward.

Seeking Alpha - 1 year ago

Mirum Pharmaceuticals And Maralixibat In Alagille Syndrome

Benzinga - 1 year ago

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) recently went public, offering 5 million shares at $15 each.

Benzinga - 1 year ago

Mirum Pharmaceuticals (NASDAQ: MIRM) made its public debut Thursday morning, opening at $13 after being priced at $15 per share.

About MIRM

Mirum Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2019
CEO
Christopher Peetz
Employees
67
Stock Exchange
NASDAQ
Ticker Symbol
MIRM
Full Company Profile

Analyst Forecasts

According to 7 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is 49.29, which is an increase of 161.62% from the latest price.

Price Target
$49.29
(161.62% upside)
Analyst Consensus: Strong Buy